UK Cardiovascular Diagnostic Testing Market Market Report 2023 to 2030

UK Cardiovascular Diagnostic Testing Market Analysis

$ 3999

UK Cardiovascular Diagnostic Testing Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2033. The market for Cardiovascular Diagnostic Testing is expanding as a result of rising geriatric population globally and increasing prevalence of chronic heart conditions. These factors are giving boost to the development of better diagnostic tools and methods for the early detection and accurate diagnosis of cardiovascular diseases. Some of the key players in the global Cardiovascular Diagnostic Testing Market include Abbott Laboratories, Agilent Technologies Inc., Becton, Dickinson and Company, Bio-Rad Laboratories Inc., CardioDx, Danaher Corporation, F. Hoffmann-La Roche Ltd, GE Healthcare, Siemens Healthineers AG, Thermo Fisher Scientific Inc.

ID: IN10GBHS029 CATEGORY: Healthcare Services GEOGRAPHY: UK AUTHOR: Dr. Nensi Savani

Buy Now

UK Cardiovascular Diagnostic Testing Market Executive Summary

UK Cardiovascular Diagnostic Testing Market is valued at around $209.6 Bn in 2022 and is projected to reach $341.6 Bn by 2030, exhibiting a CAGR of 6.3% during the forecast period 2023-2030.

The Cardiovascular Diagnostic Testing Market refers to the market for tools and methods used to diagnose cardiovascular diseases which includes both chronic and acute cardiac diseases. The market includes software and platforms for analysing and interpreting the findings of diagnostic tests, imaging methods, and biomarkers used to detect the disease.

Cardiovascular diseases are the leading cause of death, which claims around 17.9 Mn lives each year globally. Increasing burden of cardiovascular diseases has contributed to the growth of the global market for cardiovascular diagnostic testing in recent years. Advances in diagnostic technologies, such as the creation of more precise and sensitive biomarkers and imaging methodologies, are also driving the market.

There are many players in cardiovascular diagnostic testing market but Abbott Laboratories, Agilent Technologies Inc., Becton, Dickinson and Company, Bio-Rad Laboratories Inc., CardioDx, Danaher Corporation, F. Hoffmann-La Roche Ltd, GE Healthcare, Siemens Healthineers AG and Thermo Fisher Scientific Inc. are major players.

Cardiovascular diseases can be diagnosed using a variety of diagnostic procedures and tests like laboratory developed test (lipoprotein test, angiotensin test, fibrinogen test, high-sensitivity C-reactive protein (hsCRP) and in vitro diagnostic test (electrocardiogram test, echocardiography test, and transesophageal echocardiogram test). New Biomarkers like Troponin T, Galectin-3, ST2 and microRNAs are being developed for efficiency and accuracy of the diagnosis.

The ageing global population, rising knowledge and awareness of cardiovascular diseases, increasing burden of diseases, advancement in technologies and early detection are expected to boost the market for cardiovascular diagnostic testing. The market still has difficulties with regard to obtaining regulatory permission, funding for diagnostic procedures and therapies, less skilled professionals and risk of complications.

Market Dynamics

Drivers of UK Cardiovascular Diagnostic Testing Market:

Growing Incidence and Prevalence of Cardiovascular Diseases: Cardiovascular diseases are most common in worldwide population and incidence is increasing due to factors like sedentary lifestyle, Unhealthy diet, increased consumption of tobacco, rising prevalence of smoking and aging population. Recently Covid-19 has also added contribution to increase burden of disease for cardiovascular disease. All of these are raising the demand for diagnostic methods and technologies that can successfully identify the illness.

Advancement and development in diagnostic technology: The expansion of the Cardiovascular Diagnostic Testing is being driven by advancements in diagnostic technologies, which include the creation of more sensitive and specific biomarkers, imaging methods, and genetic testing.

Increasing Healthcare Expenditure: The market for Cardiovascular Diagnostic Testing is expanding as a result of rising healthcare spending in both developed and developing nations. Which will help in the development of better diagnostic tools and methods for the early detection and accurate diagnosis of cardiovascular diseases.

Growing Interest in Personalised Medicine: Diagnostic techniques play major role in formulating treatment plan based on the information of patient’s genetic and molecular makeup. As interest in personalised medicine is growing it will boost the cardiovascular diagnostic testing market.

Increasing awareness and education: People are being more aware of cardiovascular health and the need for early detection of cardiovascular disease and treatment. It has helped in increase demand for cardiovascular diagnostic testing.

Developments in Cardiovascular Diagnostic Testing Market:

The market for Cardiovascular Diagnostic Testing is always changing due to new discoveries and improvements in science and technology. Recent market developments include the following:

New Biomarkers: There are many biomarkers like Troponin T, Galectin-3, ST2 and microRNAs which are being studied for the improvement in cardiovascular diagnostic testing. It will improve efficacy and effectiveness of the diagnostic testing.

Wearable Devices: Smartwatches and fitness trackers are being developed which will help to monitor heart rate and vital signs.

Blood-Based Diagnostics: Scientists are working to create blood-based diagnostic techniques that can identify particular biomarkers linked to cardiovascular diseases, which will offer a less invasive and more accessible diagnostic option.

All these developments help to increase the precision and accessibility of diagnostic tools and techniques for cardiovascular disease.

Notable Deal in Cardiovascular Diagnostic Testing Market:

In February 2023, Cardio Diagnostics launched AI-based blood test PrecisionCHD for early detection of the coronary heart disease.

Key players

Abbott Laboratories Boston Scientific Corporation GE Healthcare Siemens Healthineers Philips Healthcare F. Hoffmann-La Roche Ltd. Alere Inc. Cardinal Health Inc. Bio-Rad Laboratories Inc. Beckman Coulter Inc.

1. Executive Summary
1.1 Service Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Healthcare Services Market in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Services
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Market Segmentations For UK Cardiovascular Diagnostic Testing Market

By Type:

Laboratory Developed Test
- Lipoprotein test
- Angiotensin test
- Fibrinogen test,
- High-sensitivity C-reactive protein (hsCRP)
In-Vitro Diagnostic Test
- Electrocardiogram test,
- Echocardiography test
- Transesophageal echocardiogram test

By End-User:

Laboratory Testing Facilities
Academic Institutes
Point-of-care Testing Facilities

By Disease:

Myocardial Infraction
Congestive Heart Failure
Acute Coronary Syndrome
Ischemia
Atherosclerosis

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.